8-K
TENET HEALTHCARE CORP (THC)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
_______________
Date of Report: July 31, 2023
(Date of earliest event reported)
_______________
TENET HEALTHCARE CORPORATION
(Exact name of Registrant as specified in its charter)
| Nevada | 1-7293 | 95-2557091 |
|---|---|---|
| (State of Incorporation) | (Commission File Number) | (IRS Employer<br>Identification Number) |
14201 Dallas Parkway
Dallas, TX 75254
(Address of principal executive offices, including zip code)
(469) 893-2200
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br>Symbol(s) | Name of each exchange <br>on which registered |
|---|---|---|
| Common stock, $0.05 par value | THC | NYSE |
| 6.875% Senior Notes due 2031 | THC31 | NYSE |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02. | Results of Operations and Financial Condition. |
|---|
The information contained herein is being furnished pursuant to Item 2.02 of Form 8-K, “Results of Operations and Financial Condition.” This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
On July 31, 2023, Tenet Healthcare Corporation (the “Company”) issued a press release reporting the financial results of the Company for the quarter ended June 30, 2023. A copy of the press release is attached to this report as Exhibit 99.1 and incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
|---|
(d)Exhibits
| Exhibit No. | Description |
|---|---|
| 99.1 | Press Release issued on July 31, 2023 |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TENET HEALTHCARE CORPORATION | ||
|---|---|---|
| Date: July 31, 2023 | By: | /s/ R. SCOTT RAMSEY |
| R. Scott Ramsey | ||
| Senior Vice President, Controller |
Document
Exhibit 99.1
Tenet Reports Second Quarter 2023 Results;
Raises 2023 Outlook
•Net income from continuing operations available to common shareholders in second quarter 2023 was $123 million, or $1.15 per diluted share
•Adjusted diluted earnings per share from continuing operations1 was $1.44 in second quarter 2023
•Consolidated Adjusted EBITDA1 in second quarter 2023 was $843 million, including $8 million of grant income
•Second quarter 2023 Ambulatory Care Adjusted EBITDA of $369 million increased 16.4% over second quarter 2022 excluding grant income
•Same-facility system-wide ambulatory surgical cases increased 6.6% versus second quarter 2022; Same-hospital admissions increased 3.0% versus second quarter 2022, with non-Covid admissions up 5%
•FY 2023 Adjusted EBITDA Outlook increased, now expected to be in the range of $3.310 billion to $3.460 billion
DALLAS — July 31, 2023 — Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended June 30, 2023.
"We have continued positive momentum through the second quarter with robust same facility volume and revenue growth in our ambulatory care segment as well as continued strength in our hospital segment," said Saum Sutaria, M.D., Chief Executive of Tenet. "Our strategic growth initiatives and operating discipline helped drive these results as we expand our patient-centered care capabilities in the communities we serve."
Page 1
Tenet’s results for second quarter 2023 versus second quarter 2022 are as follows:
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| ($ in millions, except per share results) | 2023 | 2022 | 2023 | 2022 |
| Net operating revenues | $5,082 | $4,638 | $10,103 | $9,383 |
| Net income available to Tenet common shareholders from continuing operations | $123 | $38 | $266 | $177 |
| Net income available to Tenet common shareholders from continuing operations per diluted share | $1.15 | $0.35 | $2.47 | $1.63 |
| Adjusted EBITDA1 excluding grant income | $835 | $749 | $1,664 | $1,631 |
| Adjusted EBITDA1 | $843 | $843 | $1,675 | $1,731 |
| Adjusted diluted earnings per share from continuing operations1 | $1.44 | $1.48 | $2.87 | $3.33 |
•Net income from continuing operations available to the Company’s common shareholders in the second quarter 2023 was $123 million, or $1.15 per diluted share, versus $38 million, or $0.35 per diluted share, in second quarter 2022.
•Second quarter 2023 included COVID-related stimulus grant income of $8 million pre-tax ($6 million after-tax, or $0.06 per diluted share) versus $94 million pre-tax ($71 million after-tax, or $0.65 per diluted share) in second quarter 2022.
•The Company recognized additional income tax expense for the three months ended June 30, 2023 of approximately $23 million, or $0.22 per diluted share, and $45 million, or $0.41 per diluted share for the three months ended June 30, 2022, as a result of interest expense limitation tax regulations.
•Adjusted EBITDA1 excluding grant income in second quarter 2023 was $835 million compared to $749 million in second quarter 2022, reflecting strong volume growth in our Ambulatory Care and Hospital Operations segments, and improved contract labor costs. The Company believes this strong volume growth is due in part to patient care deferred as a result of the pandemic. Second quarter 2022 results included the adverse impacts associated with a cybersecurity incident.
Page 2
Balance Sheet and Cash Flows
•Cash flows provided by operating activities for the six months ended June 30, 2023 were $1.047 billion versus $347 million for the six months ended June 30, 2022 (or $822 million excluding $475 million of repayments associated with Medicare advances).
•The Company produced free cash flow1 of $680 million for the six months ended June 30, 2023 versus $40 million for the six months ended June 30, 2022 (or $515 million excluding the repayment of Medicare advances).
•In the three months ended June 30, 2023, the Company repurchased 579,637 shares of common stock for $40 million. In the six months ended June 30, 2023, the Company repurchased 1,485,983 shares of common stock for $90 million.
•In June 2023, the Company completed a private placement of $1.350 billion in aggregate principal amount of newly issued 6.750% senior secured first lien notes maturing in 2031. The Company used the net proceeds from the sale of the notes, after payment of fees and expenses, to finance, together with cash on hand, the redemption of all $1.345 billion aggregate principal amount then outstanding of its 4.625% senior secured notes due 2024. The Company now has no significant debt maturities until 2026.
•The Company’s ratio of net debt to Adjusted EBITDA1 was 4.14x at June 30, 2023 compared to 4.19x at March 31, 2023 and 4.10x at December 31, 2022.
•The Company had no outstanding borrowings on its $1.5 billion line of credit as of June 30, 2023.
Page 3
Ambulatory Care (Ambulatory) Segment
Tenet’s Ambulatory business segment is comprised of the operations of United Surgical Partners International (USPI). As of June 30, 2023, USPI had interests in 455 ambulatory surgery centers (312 consolidated) and 24 surgical hospitals (eight consolidated) in 35 states. For all periods prior to June 30, 2022, the Company owned 95% of the voting stock of USPI and now owns 100%.
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| Ambulatory segment results ($ in millions) | 2023 | 2022 | 2023 | 2022 |
| Revenues | ||||
| Net operating revenues | $942 | $771 | $1,847 | $1,509 |
| Same-facility system-wide net patient service revenues2 | $1,721 | $1,568 | $3,358 | $3,065 |
| Volume Changes versus the Prior-Year Period | ||||
| Same-facility system-wide surgical cases2 | 6.6% | (0.9)% | 7.2% | 3.3% |
| Same-facility system-wide surgical cases on same-business day basis2 | 6.6% | (0.9)% | 7.2% | 2.4% |
| Adjusted EBITDA, Margins and Noncontrolling Interest (NCI) | ||||
| Adjusted EBITDA excluding grant income | $369 | $317 | $709 | $597 |
| Adjusted EBITDA | $370 | $319 | $710 | $601 |
| Adjusted EBITDA margin excluding grant income | 39.2% | 41.1% | 38.4% | 39.6% |
| Adjusted EBITDA margin | 39.3% | 41.4% | 38.4% | 39.8% |
| Adjusted EBITDA less facility-level NCI excluding grant income | $231 | $209 | $445 | $395 |
| Adjusted EBITDA less facility-level NCI | $231 | $210 | $445 | $397 |
| Adjusted EBITDA less total NCI excluding grant income | $231 | $204 | $445 | $386 |
| Adjusted EBITDA less total NCI | $231 | $205 | $445 | $388 |
•Second quarter 2023 net operating revenues increased 22.2% compared to second quarter 2022 driven by strong same-facility net surgical case growth, acquisitions and opening of new facilities, service line growth and improved pricing yield.
•Surgical business same-facility system-wide net patient service revenues increased 9.8% in second quarter 2023 compared to second quarter 2022, with cases up 6.6% and net revenue per case up 2.9%.
•Second quarter 2023 Adjusted EBITDA excluding grant income increased 16.4% relative to second quarter 2022, due to strong same-facility system-wide surgical case growth, contributions from acquisitions and de novo facilities, improved pricing yield, and effective expense management.
•Adjusted EBITDA margin excluding grant income in the second quarter 2023 declined relative to second quarter 2022 primarily due to higher other operating expenses partially offset by improved salaries, wages and benefits.
Page 4
Hospital Operations and Other (Hospital) Segment
Tenet’s Hospital business segment is primarily comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro-hospitals and physician practices.
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| Hospital segment results ($ in millions) | 2023 | 2022 | 2023 | 2022 |
| Revenues | ||||
| Net operating revenues (prior to inter-segment eliminations) | $3,922 | $3,645 | $7,821 | $7,443 |
| Grant income | $7 | $92 | $10 | $96 |
| Same-hospital net patient service revenues3 | $3,590 | $3,344 | $7,137 | $6,851 |
| Same-Hospital Volume Changes versus the Prior-Year Period | ||||
| Admissions | 3.0% | (8.1)% | 3.6% | (6.4)% |
| Adjusted admissions4 | 3.2% | (5.3)% | 4.9% | (3.5)% |
| Outpatient visits (including outpatient ER visits) | (1.3)% | (10.0)% | (0.6)% | (4.7)% |
| Emergency Room visits (inpatient and outpatient) | 0.4% | 3.8% | 2.5% | 8.5% |
| Hospital surgeries | (0.1)% | (8.0)% | 1.1% | (4.3)% |
| Adjusted EBITDA | ||||
| Adjusted EBITDA excluding grant income | $381 | $339 | $783 | $849 |
| Adjusted EBITDA | $388 | $431 | $793 | $945 |
| Adjusted EBITDA margin excluding grant income | 9.7% | 9.3% | 10.0% | 11.4% |
| Adjusted EBITDA margin | 9.9% | 11.8% | 10.1% | 12.7% |
•Second quarter 2023 net operating revenues increased 7.6% from second quarter 2022 primarily due to increased adjusted admissions, improved pricing yield, and the adverse impacts associated with a cybersecurity incident in the second quarter of 2022.
•Same-hospital net patient service revenue per adjusted admission increased 4.0% year-over-year for second quarter 2023 primarily due to improved pricing yield and our focus on growing higher acuity services. COVID admissions were 2% of total admissions in the second quarter 2023 versus 3% in the second quarter 2022. Second quarter non-COVID inpatient admissions increased 5% over second quarter 2022.
•Adjusted EBITDA excluding grant income in second quarter 2023 was $381 million compared to $339 million in second quarter 2022, reflecting strong adjusted admissions growth and improved contract labor costs, partially offset by higher other operating expenses. Second quarter 2022 results included the adverse impacts associated with a cybersecurity incident.
Page 5
Conifer Segment
Tenet’s Conifer business segment provides comprehensive end-to-end and focused-point business process services, including hospital and physician revenue cycle management, patient communications and engagement support and value-based care solutions to hospitals, health systems, physician practices, employers, and other clients.
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| Conifer segment results ($ in millions) | 2023 | 2022 | 2023 | 2022 |
| Net operating revenues | $323 | $333 | $647 | $657 |
| Adjusted EBITDA | $85 | $93 | $172 | $185 |
| Adjusted EBITDA margin | 26.3% | 27.9% | 26.6% | 28.2% |
•Second quarter 2023 net operating revenues declined 3.0% compared to second quarter 2022 reflecting previously announced contract changes with Tenet hospitals.
•Second quarter 2023 Adjusted EBITDA and Adjusted EBITDA margin declined compared to second quarter 2022 reflecting the aforementioned contract changes.
Page 6
2023 Outlook1
Tenet’s Outlook for full year 2023 (consolidated and by segment) and third quarter 2023 follows:
| CONSOLIDATED ($ in millions, except per share amounts) | FY 2023 Outlook |
|---|---|
| Net operating revenues | 20,100 to 20,500 |
| Income from continuing operations available to Tenet common stockholders | 447 to 582 |
| Adjusted EBITDA | 3,310 to 3,460 |
| Adjusted EBITDA margin | 16.5% to 16.9% |
| Diluted income per common share from continuing operations | 4.19 to 5.48 |
| Adjusted net income from continuing operations | 550 to 640 |
| Adjusted diluted earnings per share from continuing operations | 5.18 to 6.03 |
| Equity in earnings of unconsolidated affiliates | 200 to 220 |
| Depreciation and amortization | 850 to 875 |
| Interest expense | 895 to 905 |
| Income tax expense5 | 315 to 335 |
| Net income available to NCI | 660 to 700 |
| Weighted average diluted common shares | ~105 million |
| NCI cash distributions | 565 to 605 |
| Net cash provided by operating activities | 1,775 to 2,075 |
| Adjusted net cash provided by operating activities | 1,925 to 2,175 |
| Capital expenditures | 675 to 725 |
| Free cash flow | 1,100 to 1,350 |
| Adjusted free cash flow – continuing operations | 1,250 to 1,450 |
All values are in US Dollars.
Page 7
| Ambulatory Segment ($ in millions) | FY 2023 Outlook | |||
|---|---|---|---|---|
| Net operating revenues | $3,725 to $3,825 | |||
| Adjusted EBITDA | $1,490 to $1,530 | |||
| Total NCI (Facility level) | $545 to $565 | |||
| Adjusted EBITDA less total NCI | $945 to $965 | |||
| Changes versus prior year6: | ||||
| Surgical cases volumes | Up 5.0% to 6.0% | |||
| Net revenues per surgical case | Up 2.0% to 3.0% | |||
| Hospital Segment ($ in millions) | FY 2023 Outlook | |||
| --- | --- | |||
| Net operating revenues (prior to inter-segment eliminations) | $15,540 to $15,790 | |||
| Adjusted EBITDA | $1,490 to $1,590 | |||
| NCI | $25 to $40 | |||
| Changes versus prior year6: | ||||
| Inpatient admissions | Up 2.0% to 4.0% | |||
| Adjusted admissions | Up 2.5% to 4.5% | Conifer Segment ($ in millions) | FY 2023 Outlook | |
| --- | --- | |||
| Net operating revenues | $1,285 to $1,335 | |||
| Adjusted EBITDA | $330 to $340 | |||
| NCI | $90 to $95 |
Management’s Webcast Discussion of Results
Tenet management will discuss the Company’s second quarter 2023 results in a webcast scheduled for 5:00 p.m. Eastern Time (4:00 p.m. Central Time) on July 31, 2023. Investors can access the webcast through the Company’s website at www.tenethealth.com/investors.
The slide presentation associated with the webcast referenced above, a copy of this earnings press release, and a related supplemental financial disclosures document will be available on the Company’s Investor Relations website on July 31, 2023.
Page 8
Cautionary Statement
This release contains “forward-looking statements” - that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain, especially with regards to developments related to COVID-19. Particular uncertainties that could cause the Company’s actual results to be materially different than those expressed in the Company’s forward-looking statements include, but are not limited to the impact of the COVID-19 pandemic, and other factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2022 and other filings with the Securities and Exchange Commission.
Footnotes
1.Tables and discussions throughout this earnings release include certain financial measures, including those related to our second quarter and full year 2023 Outlook, that are not in accordance with accounting principles generally accepted in the United States of America (GAAP). Reconciliations of GAAP measures to the Adjusted (non-GAAP) measures used are detailed in Tables #1-6 included at the end of this earnings release. Management’s reasoning for the use of these non-GAAP measures and descriptions of the various non-GAAP measures are included in the Non-GAAP Financial Measures section of this earnings release.
2.Same-facility system-wide revenues and statistical information include the results of the facilities in which the Ambulatory segment has an investment that are not consolidated by Tenet. To help analyze the segment’s results of operations, management uses system-wide measures, which include revenues and cases of both consolidated and unconsolidated facilities.
3.For 2023, same-hospital revenues and statistical data include those for hospitals and hospital-affiliated outpatient centers operated by the Company’s Hospital segment continuously from January 1, 2022 through June 30, 2023. Amounts associated with physician practices are excluded.
4.Adjusted admissions represent actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues, then dividing that result by gross inpatient revenues.
5.Income tax expense is calculated by multiplying 24% (the federal corporate tax rate of 21% plus an estimate of state taxes) by the sum of: pretax income less GAAP facility level NCI expense plus permanent differences, and non-deductible interest expense.
6.Change versus prior year is presented on a same-facility system-wide basis for USPI Ambulatory surgical cases and on a same-hospital basis for hospital statistics.
Page 9
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates or has ownership interests in more than 475 ambulatory surgery centers and surgical hospitals. We also operate 61 acute care and specialty hospitals, approximately 110 other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.
Contact Information
| Investor Contact | Media Contact |
|---|---|
| Will McDowell | Robert Dyer |
| 469-893-2387 | 469-893-2640 |
| william.mcdowell@tenethealth.com | mediarelations@tenethealth.com |
Page 10
Non-GAAP Financial Measures
The Company believes the non-GAAP measures described below are useful to investors and analysts because they present additional information on the Company’s financial performance. Investors, analysts, Company management and the Company’s Board of Directors utilize these non-GAAP measures, in addition to GAAP measures, to track the Company’s financial and operating performance and compare the Company’s performance to its peer companies, which use similar non-GAAP financial measures in their presentations and earnings releases. The Human Resources Committee of the Company’s Board of Directors also uses certain of these measures to evaluate management’s performance for the purpose of determining incentive compensation. Additional information regarding the purpose and utility of specific non-GAAP measures used in this release is set forth below.
•Adjusted EBITDA is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) the cumulative effect of changes in accounting principles, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, net of tax, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non-operating income (expense), net, (7) interest expense, (8) litigation and investigation benefit (costs), net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization and (12) income (loss) from divested and closed businesses (i.e., health plan businesses). Litigation and investigation costs excluded do not include ordinary course of business malpractice and other litigation and related expenses.
•Adjusted diluted earnings (loss) per share from continuing operations is defined by the Company as Adjusted net income available (loss attributable) from continuing operations to Tenet common shareholders, divided by the weighted average diluted shares outstanding in the reporting period.
•Adjusted net income available (loss attributable) from continuing operations to Tenet common shareholders is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) income (loss) from discontinued operations, net of tax, (2) gain (loss) from early extinguishment of debt, (3) litigation and investigation benefit (costs), net of insurance recoveries, (4) net gains (losses) on sales, consolidation and deconsolidation of facilities, (5) impairment and restructuring charges and acquisition-related costs, (6) income (loss) from divested and closed businesses (i.e., health plan businesses) and (7) the associated impact of these items on taxes and noncontrolling interests. Litigation and investigation costs excluded do not include ordinary course of business malpractice and other litigation and related expenses.
•Free Cash Flow is defined by the Company as (1) net cash provided by (used in) operating activities, less (2) purchases of property and equipment for continuing operations.
•Adjusted Free Cash Flow is defined by the Company as (1) Adjusted net cash provided by (used in) operating activities from continuing operations, less (2) purchases of property and equipment from continuing operations.
•Adjusted net cash provided by (used in) operating activities is defined by the Company as cash provided by (used in) operating activities prior to (1) payments for restructuring charges, acquisition-related costs and litigation costs and settlements, and (2) net cash provided by (used in) operating activities from discontinued operations.
The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to other GAAP and non-GAAP measures, as factors in determining the estimated fair value of shares of the Company’s common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance.
The Company uses, and believes investors use, Free Cash Flow and Adjusted Free Cash Flow as supplemental non-GAAP measures to analyze cash flows generated from the Company’s operations. The Company believes these measures are useful to investors in evaluating its ability to fund distributions paid to noncontrolling interests or for acquisitions, purchasing equity interests in joint ventures or repaying debt.
These non-GAAP measures may not be comparable to similarly titled measures reported by other companies. Because these measures exclude many items that are included in the Company’s financial statements, they do not provide a complete measure of the Company’s operating performance. For example, the Company’s definitions of Free Cash Flow and Adjusted Free Cash Flow do not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows from Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, or (ii) distributions paid to noncontrolling interests. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company’s financial performance.
See corresponding reconciliations of the non-GAAP financial measures referred to above to the most comparable GAAP financial measures in Tables #1 - 6 below.
Page 11
Tenet Healthcare Corporation
Financial Statements and Reconciliations
Second Quarter Earnings Release
Table of Contents
| Description | Page |
|---|---|
| Consolidated Statements of Operations | 13 |
| Consolidated Balance Sheets | 15 |
| Consolidated Statements of Cash Flows | 16 |
| Segment Reporting | 17 |
| Table #1–Reconciliations of NetIncometoAdjusted Net Income | 18 |
| Table #2–Reconciliations of Net Income toAdjusted EBITDA | 19 |
| Table #3–Reconciliations of Net Cash Provided by Operating Activities to Free Cash Flow and Adjusted Free Cash Flow | 20 |
| Table #4–Reconciliations of Outlook Net Income to Outlook Adjusted Net Income | 21 |
| Table #5– Reconciliations of Outlook Net Income to Outlook Adjusted EBITDA | 22 |
| Table #6–Reconciliations of Outlook Net Cash Provided byOperating Activities to Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow | 23 |
Page 12
TENET HEALTHCARE CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| (Dollars in millions, except per share amounts) | Three Months Ended June 30, | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | % | 2022 | % | Change | |||||||||||
| Net operating revenues | $ | 5,082 | 100.0 | % | $ | 4,638 | 100.0 | % | 9.6 | % | |||||
| Grant income | 8 | 0.2 | % | 94 | 2.0 | % | (91.5) | % | |||||||
| Equity in earnings of unconsolidated affiliates | 54 | 1.1 | % | 54 | 1.2 | % | — | % | |||||||
| Operating expenses: | |||||||||||||||
| Salaries, wages and benefits | 2,285 | 45.0 | % | 2,126 | 45.8 | % | 7.5 | % | |||||||
| Supplies | 891 | 17.5 | % | 811 | 17.5 | % | 9.9 | % | |||||||
| Other operating expenses, net | 1,125 | 22.1 | % | 1,006 | 21.7 | % | 11.8 | % | |||||||
| Depreciation and amortization | 213 | 4.3 | % | 216 | 4.7 | % | |||||||||
| Impairment and restructuring charges, and acquisition-related costs | 16 | 0.3 | % | 57 | 1.2 | % | |||||||||
| Litigation and investigation costs | 10 | 0.2 | % | 18 | 0.4 | % | |||||||||
| Net gains on sales, consolidation and deconsolidation of facilities | — | — | % | (1) | — | % | |||||||||
| Operating income | 604 | 11.9 | % | 553 | 11.9 | % | |||||||||
| Interest expense | (226) | (222) | |||||||||||||
| Other non-operating income, net | 6 | — | |||||||||||||
| Loss from early extinguishment of debt | (11) | (66) | |||||||||||||
| Income from continuing operations, before income taxes | 373 | 265 | |||||||||||||
| Income tax expense | (80) | (86) | |||||||||||||
| Net income | 293 | 179 | |||||||||||||
| Less: Net income available to noncontrolling interests | 170 | 141 | |||||||||||||
| Net income available to Tenet Healthcare Corporation common shareholders | $ | 123 | $ | 38 | |||||||||||
| Earnings per share available to Tenet Healthcare Corporation common shareholders: | |||||||||||||||
| Basic | |||||||||||||||
| Continuing operations | $ | 1.21 | $ | 0.35 | |||||||||||
| Diluted | |||||||||||||||
| Continuing operations | $ | 1.15 | $ | 0.35 | |||||||||||
| Weighted average shares and dilutive securities outstanding<br> (in thousands): | |||||||||||||||
| Basic | 101,766 | 107,790 | |||||||||||||
| Diluted | 104,778 | 108,750 |
Page 13
TENET HEALTHCARE CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| (Dollars in millions, except per share amounts) | Six Months Ended June 30, | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | % | 2022 | % | Change | |||||||||||
| Net operating revenues | $ | 10,103 | 100.0 | % | $ | 9,383 | 100.0 | % | 7.7 | % | |||||
| Grant income | 11 | 0.1 | % | 100 | 1.1 | % | (89.0) | % | |||||||
| Equity in earnings of unconsolidated affiliates | 104 | 1.0 | % | 100 | 1.1 | % | 4.0 | % | |||||||
| Operating expenses: | |||||||||||||||
| Salaries, wages and benefits | 4,543 | 45.0 | % | 4,308 | 45.9 | % | 5.5 | % | |||||||
| Supplies | 1,782 | 17.6 | % | 1,596 | 17.0 | % | 11.7 | % | |||||||
| Other operating expenses, net | 2,218 | 22.0 | % | 1,948 | 20.8 | % | 13.9 | % | |||||||
| Depreciation and amortization | 430 | 4.2 | % | 419 | 4.5 | % | |||||||||
| Impairment and restructuring charges, and acquisition-related costs | 37 | 0.4 | % | 73 | 0.8 | % | |||||||||
| Litigation and investigation costs | 14 | 0.1 | % | 38 | 0.4 | % | |||||||||
| Net gains on sales, consolidation and deconsolidation of facilities | (13) | (0.1) | % | — | — | % | |||||||||
| Operating income | 1,207 | 11.9 | % | 1,201 | 12.8 | % | |||||||||
| Interest expense | (447) | (449) | |||||||||||||
| Other non-operating income, net | 4 | — | |||||||||||||
| Loss from early extinguishment of debt | (11) | (109) | |||||||||||||
| Income from continuing operations, before income taxes | 753 | 643 | |||||||||||||
| Income tax expense | (164) | (185) | |||||||||||||
| Income from continuing operations, before discontinued operations | 589 | 458 | |||||||||||||
| Income from discontinued operations | — | 1 | |||||||||||||
| Net income | 589 | 459 | |||||||||||||
| Less: Net income available to noncontrolling interests | 323 | 281 | |||||||||||||
| Net income available to Tenet Healthcare Corporation common shareholders | $ | 266 | $ | 178 | |||||||||||
| Amounts available to Tenet Healthcare Corporation common shareholders | |||||||||||||||
| Income from continuing operations, net of tax | $ | 266 | $ | 177 | |||||||||||
| Income from discontinued operations, net of tax | — | 1 | |||||||||||||
| Net income available to Tenet Healthcare Corporation common shareholders | $ | 266 | $ | 178 | |||||||||||
| Earnings per share available to Tenet Healthcare Corporation common shareholders: | |||||||||||||||
| Basic | |||||||||||||||
| Continuing operations | $ | 2.61 | $ | 1.64 | |||||||||||
| Discontinued operations | — | 0.01 | |||||||||||||
| $ | 2.61 | $ | 1.65 | ||||||||||||
| Diluted | |||||||||||||||
| Continuing operations | $ | 2.47 | $ | 1.63 | |||||||||||
| Discontinued operations | — | 0.01 | |||||||||||||
| $ | 2.47 | $ | 1.64 | ||||||||||||
| Weighted average shares and dilutive securities outstanding <br> (in thousands): | |||||||||||||||
| Basic | 102,028 | 107,636 | |||||||||||||
| Diluted | 105,354 | 114,054 |
Page 14
TENET HEALTHCARE CORPORATION
CONSOLIDATED BALANCE SHEETS
(Unaudited)
| (Dollars in millions) | June 30, | December 31, | ||||
|---|---|---|---|---|---|---|
| 2023 | 2022 | |||||
| ASSETS | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 934 | $ | 858 | ||
| Accounts receivable | 2,914 | 2,943 | ||||
| Inventories of supplies, at cost | 404 | 405 | ||||
| Assets held for sale | 141 | — | ||||
| Other current assets | 1,602 | 1,775 | ||||
| Total current assets | 5,995 | 5,981 | ||||
| Investments and other assets | 3,130 | 3,147 | ||||
| Deferred income taxes | 8 | 19 | ||||
| Property and equipment, at cost, less accumulated depreciation and amortization | 6,268 | 6,462 | ||||
| Goodwill | 10,350 | 10,123 | ||||
| Other intangible assets, at cost, less accumulated amortization | 1,406 | 1,424 | ||||
| Total assets | $ | 27,157 | $ | 27,156 | ||
| LIABILITIES AND EQUITY | ||||||
| Current liabilities: | ||||||
| Current portion of long-term debt | $ | 141 | $ | 145 | ||
| Accounts payable | 1,246 | 1,504 | ||||
| Accrued compensation and benefits | 718 | 778 | ||||
| Professional and general liability reserves | 257 | 255 | ||||
| Accrued interest payable | 199 | 213 | ||||
| Liabilities held for sale | 17 | — | ||||
| Contract liabilities | 76 | 110 | ||||
| Other current liabilities | 1,498 | 1,471 | ||||
| Total current liabilities | 4,152 | 4,476 | ||||
| Long-term debt, net of current portion | 14,907 | 14,934 | ||||
| Professional and general liability reserves | 793 | 790 | ||||
| Defined benefit plan obligations | 329 | 331 | ||||
| Deferred income taxes | 243 | 217 | ||||
| Other long-term liabilities | 1,732 | 1,800 | ||||
| Total liabilities | 22,156 | 22,548 | ||||
| Commitments and contingencies | ||||||
| Redeemable noncontrolling interests in equity of consolidated subsidiaries | 2,277 | 2,149 | ||||
| Equity: | ||||||
| Shareholders’ equity: | ||||||
| Common stock | 8 | 8 | ||||
| Additional paid-in capital | 4,800 | 4,778 | ||||
| Accumulated other comprehensive loss | (178) | (181) | ||||
| Accumulated deficit | (537) | (803) | ||||
| Common stock in treasury, at cost | (2,750) | (2,660) | ||||
| Total shareholders’ equity | 1,343 | 1,142 | ||||
| Noncontrolling interests | 1,381 | 1,317 | ||||
| Total equity | 2,724 | 2,459 | ||||
| Total liabilities and equity | $ | 27,157 | $ | 27,156 |
Page 15
TENET HEALTHCARE CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| (Dollars in millions) | Six Months Ended | |||||
|---|---|---|---|---|---|---|
| June 30, | ||||||
| 2023 | 2022 | |||||
| Net income | $ | 589 | $ | 459 | ||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||
| Depreciation and amortization | 430 | 419 | ||||
| Deferred income tax expense | 37 | 132 | ||||
| Stock-based compensation expense | 33 | 34 | ||||
| Impairment and restructuring charges, and acquisition-related costs | 37 | 73 | ||||
| Litigation and investigation costs | 14 | 38 | ||||
| Net gains on sales, consolidation and deconsolidation of facilities | (13) | — | ||||
| Loss from early extinguishment of debt | 11 | 109 | ||||
| Equity in earnings of unconsolidated affiliates, net of distributions received | 7 | 18 | ||||
| Amortization of debt discount and debt issuance costs | 18 | 15 | ||||
| Pre-tax income from discontinued operations | — | (1) | ||||
| Net gains from the sale of investments and long-lived assets | (15) | (71) | ||||
| Other items, net | (3) | 12 | ||||
| Changes in cash from operating assets and liabilities: | ||||||
| Accounts receivable | 7 | (74) | ||||
| Inventories and other current assets | 160 | 173 | ||||
| Income taxes | (31) | (86) | ||||
| Accounts payable, accrued expenses, contract liabilities and other current liabilities | (168) | (764) | ||||
| Other long-term liabilities | 12 | (41) | ||||
| Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements | (78) | (98) | ||||
| Net cash provided by operating activities | 1,047 | 347 | ||||
| Cash flows from investing activities: | ||||||
| Purchases of property and equipment | (367) | (307) | ||||
| Purchases of businesses or joint venture interests, net of cash acquired | (96) | (66) | ||||
| Proceeds from sales of facilities and other assets | 16 | 209 | ||||
| Proceeds from sales of marketable securities, long-term investments and other assets | 26 | 9 | ||||
| Purchases of marketable securities and equity investments | (37) | (41) | ||||
| Other items, net | (9) | (4) | ||||
| Net cash used in investing activities | (467) | (200) | ||||
| Cash flows from financing activities: | ||||||
| Repayments of borrowings | (1,437) | (2,744) | ||||
| Proceeds from borrowings | 1,362 | 2,013 | ||||
| Repurchases of common stock | (90) | — | ||||
| Debt issuance costs | (15) | (24) | ||||
| Distributions paid to noncontrolling interests | (270) | (310) | ||||
| Proceeds from the sale of noncontrolling interests | 30 | 9 | ||||
| Purchases of noncontrolling interests | (79) | (29) | ||||
| Other items, net | (5) | (75) | ||||
| Net cash used in financing activities | (504) | (1,160) | ||||
| Net increase (decrease) in cash and cash equivalents | 76 | (1,013) | ||||
| Cash and cash equivalents at beginning of period | 858 | 2,364 | ||||
| Cash and cash equivalents at end of period | $ | 934 | $ | 1,351 | ||
| Supplemental disclosures: | ||||||
| Interest paid, net of capitalized interest | $ | (445) | $ | (416) | ||
| Income tax payments, net | $ | (158) | $ | (140) |
Page 16
TENET HEALTHCARE CORPORATION
SEGMENT REPORTING
(Unaudited)
| Three Months Ended | Six Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 30, | June 30, | |||||||||||
| (Dollars in millions) | 2023 | 2022 | 2023 | 2022 | ||||||||
| Net operating revenues: | ||||||||||||
| Ambulatory Care | $ | 942 | $ | 771 | $ | 1,847 | $ | 1,509 | ||||
| Hospital Operations and other (prior to inter-segment eliminations) | 3,922 | 3,645 | 7,821 | 7,443 | ||||||||
| Conifer | ||||||||||||
| Tenet | 105 | 111 | 212 | 226 | ||||||||
| Other clients | 218 | 222 | 435 | 431 | ||||||||
| Total Conifer revenues | 323 | 333 | 647 | 657 | ||||||||
| Inter-segment eliminations | (105) | (111) | (212) | (226) | ||||||||
| Total | $ | 5,082 | $ | 4,638 | $ | 10,103 | $ | 9,383 | ||||
| Equity in earnings of unconsolidated affiliates: | ||||||||||||
| Ambulatory Care | $ | 52 | $ | 52 | $ | 99 | $ | 94 | ||||
| Hospital Operations and other | 2 | 2 | 5 | 6 | ||||||||
| Total | $ | 54 | $ | 54 | $ | 104 | $ | 100 | ||||
| Adjusted EBITDA (including grant income): | ||||||||||||
| Ambulatory Care | $ | 370 | $ | 319 | $ | 710 | $ | 601 | ||||
| Hospital Operations and other | 388 | 431 | 793 | 945 | ||||||||
| Conifer | 85 | 93 | 172 | 185 | ||||||||
| Total | $ | 843 | $ | 843 | $ | 1,675 | $ | 1,731 | ||||
| Adjusted EBITDA margins (including grant income): | ||||||||||||
| Ambulatory Care | 39.3 | % | 41.4 | % | 38.4 | % | 39.8 | % | ||||
| Hospital Operations and other | 9.9 | % | 11.8 | % | 10.1 | % | 12.7 | % | ||||
| Conifer | 26.3 | % | 27.9 | % | 26.6 | % | 28.2 | % | ||||
| Total | 16.6 | % | 18.2 | % | 16.6 | % | 18.4 | % | ||||
| Adjusted EBITDA margins (excluding grant income): | ||||||||||||
| Ambulatory Care | 39.2 | % | 41.1 | % | 38.4 | % | 39.6 | % | ||||
| Hospital Operations and other | 9.7 | % | 9.3 | % | 10.0 | % | 11.4 | % | ||||
| Conifer | 26.3 | % | 27.9 | % | 26.6 | % | 28.2 | % | ||||
| Total | 16.4 | % | 16.1 | % | 16.5 | % | 17.4 | % | ||||
| Capital expenditures: | ||||||||||||
| Ambulatory Care | $ | 20 | $ | 19 | $ | 38 | $ | 40 | ||||
| Hospital Operations and other | 109 | 130 | 324 | 262 | ||||||||
| Conifer | 3 | 3 | 5 | 5 | ||||||||
| Total | $ | 132 | $ | 152 | $ | 367 | $ | 307 |
Page 17
TENET HEALTHCARE CORPORATION
Additional Supplemental Non-GAAP disclosures
Table #1 – Reconciliations of Net Income Available to Tenet Healthcare Corporation Common Shareholders to Adjusted Net Income Available from Continuing Operations to Common Shareholders
(Unaudited)
| Three Months Ended | Six Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|
| June 30, | June 30, | |||||||
| (Dollars in millions, except per share amounts) | 2023 | 2022 | 2023 | 2022 | ||||
| Net income available to Tenet Healthcare Corporation common shareholders | $ | 123 | $ | 38 | $ | 266 | $ | 178 |
| Net income from discontinued operations | — | — | — | 1 | ||||
| Net income from continuing operations | 123 | 38 | 266 | 177 | ||||
| Less: Impairment and restructuring charges, and acquisition-related costs | (16) | (57) | (37) | (73) | ||||
| Litigation and investigation costs | (10) | (18) | (14) | (38) | ||||
| Net gains on sales, consolidation and deconsolidation of facilities | — | 1 | 13 | — | ||||
| Loss from early extinguishment of debt | (11) | (66) | (11) | (109) | ||||
| Tax and noncontrolling interests impact of above items | 6 | 17 | 7 | 26 | ||||
| Adjusted net income available from continuing operations to common shareholders | $ | 154 | $ | 161 | $ | 308 | $ | 371 |
| Diluted earnings per share from continuing operations | $ | 1.15 | $ | 0.35 | $ | 2.47 | $ | 1.63 |
| Less: Impairment and restructuring charges, and acquisition-related costs | (0.15) | (0.52) | (0.35) | (0.64) | ||||
| Litigation and investigation costs | (0.10) | (0.17) | (0.13) | (0.33) | ||||
| Net gains on sales, consolidation and deconsolidation of facilities | — | 0.01 | 0.12 | — | ||||
| Loss from early extinguishment of debt | (0.10) | (0.61) | (0.10) | (0.96) | ||||
| Tax and noncontrolling interests impact of above items | 0.06 | 0.16 | 0.06 | 0.23 | ||||
| Adjusted diluted earnings per share from continuing operations | $ | 1.44 | $ | 1.48 | $ | 2.87 | $ | 3.33 |
| Weighted average basic shares outstanding (in thousands) | 101,766 | 107,790 | 102,028 | 107,636 | ||||
| Weighted average dilutive shares outstanding (in thousands) | 104,778 | 108,750 | 105,354 | 114,054 |
Page 18
TENET HEALTHCARE CORPORATION
Additional Supplemental Non-GAAP disclosures
Table #2 – Reconciliations of Net Income Available to Tenet Healthcare Corporation Common Shareholders to Adjusted EBITDA
(Unaudited)
| Three Months Ended | Six Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 30, | June 30, | |||||||||||
| (Dollars in millions) | 2023 | 2022 | 2023 | 2022 | ||||||||
| Net income available to Tenet Healthcare Corporation common shareholders | $ | 123 | $ | 38 | $ | 266 | $ | 178 | ||||
| Less: Net income available to noncontrolling interests | (170) | (141) | (323) | (281) | ||||||||
| Income from discontinued operations, net of tax | — | — | — | 1 | ||||||||
| Income from continuing operations | 293 | 179 | 589 | 458 | ||||||||
| Income tax expense | (80) | (86) | (164) | (185) | ||||||||
| Loss from early extinguishment of debt | (11) | (66) | (11) | (109) | ||||||||
| Other non-operating income, net | 6 | — | 4 | — | ||||||||
| Interest expense | (226) | (222) | (447) | (449) | ||||||||
| Operating income | 604 | 553 | 1,207 | 1,201 | ||||||||
| Litigation and investigation costs | (10) | (18) | (14) | (38) | ||||||||
| Net gains on sales, consolidation and deconsolidation of facilities | — | 1 | 13 | — | ||||||||
| Impairment and restructuring charges, and acquisition-related costs | (16) | (57) | (37) | (73) | ||||||||
| Depreciation and amortization | (213) | (216) | (430) | (419) | ||||||||
| Adjusted EBITDA | $ | 843 | $ | 843 | $ | 1,675 | $ | 1,731 | ||||
| Net operating revenues | $ | 5,082 | $ | 4,638 | $ | 10,103 | $ | 9,383 | ||||
| Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues | 2.4 | % | 0.8 | % | 2.6 | % | 1.9 | % | ||||
| Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin) | 16.6 | % | 18.2 | % | 16.6 | % | 18.4 | % |
Page 19
TENET HEALTHCARE CORPORATION
Additional Supplemental Non-GAAP disclosures
Table #3 – Reconciliations of Net Cash Provided by Operating Activities to Free Cash Flow and Adjusted Free Cash Flow from Continuing Operations
(Unaudited)
| (Dollars in millions) | 2023 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 | YTD | |||||||||||||
| Net cash provided by operating activities | $ | 598 | $ | 1,047 | ||||||||||
| Purchases of property and equipment | (132) | (367) | ||||||||||||
| Free cash flow – continuing operations | $ | 466 | $ | 680 | ||||||||||
| Net cash used in investing activities | $ | (181) | $ | (467) | ||||||||||
| Net cash used in financing activities | $ | (249) | $ | (504) | ||||||||||
| Net cash provided by operating activities | $ | 598 | $ | 1,047 | ||||||||||
| Less: Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements | (54) | (78) | ||||||||||||
| Adjusted net cash provided by operating activities from continuing operations | 652 | 1,125 | ||||||||||||
| Purchases of property and equipment | (132) | (367) | ||||||||||||
| Adjusted free cash flow – continuing operations | $ | 520 | $ | 758 | (Dollars in millions) | 2022 | ||||||||
| --- | --- | --- | --- | --- | --- | --- | ||||||||
| Q2 | YTD | |||||||||||||
| Net cash provided by operating activities | $ | 119 | $ | 347 | ||||||||||
| Purchases of property and equipment | (152) | (307) | ||||||||||||
| Free cash flow | (33) | 40 | ||||||||||||
| Add back: Medicare Advance Repayments | 281 | 475 | ||||||||||||
| Free cash flow – continuing operations, excluding repayments of Medicare Advances | $ | 248 | $ | 515 | ||||||||||
| Net cash used in investing activities | $ | (140) | $ | (200) | ||||||||||
| Net cash used in financing activities | $ | (33) | $ | (1,160) | ||||||||||
| Net cash provided by operating activities | $ | 119 | $ | 347 | ||||||||||
| Less: Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements | (42) | (98) | ||||||||||||
| Adjusted net cash provided by operating activities from continuing operations | 161 | 445 | ||||||||||||
| Purchases of property and equipment | (152) | (307) | ||||||||||||
| Adjusted free cash flow – continuing operations | 9 | 138 | ||||||||||||
| Add back: Medicare Advance Repayments | 281 | 475 | ||||||||||||
| Adjusted free cash flow – continuing operations, excluding repayments of Medicare Advances | $ | 290 | $ | 613 |
Page 20
TENET HEALTHCARE CORPORATION
Additional Supplemental Non-GAAP disclosures
Table #4 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted Net Income Available from Continuing Operations to Common Shareholders
(Unaudited)
| Third Quarter 2023 | FY 2023 | |||||||
|---|---|---|---|---|---|---|---|---|
| (Dollars in millions, except per share amounts) | Low | High | Low | High | ||||
| Net income available to Tenet Healthcare Corporation common shareholders | $ | 75 | $ | 120 | $ | 447 | $ | 582 |
| Less: Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1) | (30) | (20) | (125) | (75) | ||||
| Net gains on sales, consolidation and deconsolidation of facilities | — | — | 13 | 13 | ||||
| Loss from early extinguishment of debt(2) | — | — | (11) | (11) | ||||
| Tax and noncontrolling interests impact of above items | 5 | 5 | 20 | 15 | ||||
| Adjusted net income available from continuing operations to common shareholders | $ | 100 | $ | 135 | $ | 550 | $ | 640 |
| Diluted earnings per share from continuing operations | $ | 0.71 | $ | 1.13 | $ | 4.19 | $ | 5.48 |
| Less: Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements | (0.28) | (0.20) | (1.20) | (0.71) | ||||
| Net gains on sales, consolidation and deconsolidation of facilities | — | — | 0.12 | 0.12 | ||||
| Loss from early extinguishment of debt | — | — | (0.10) | (0.10) | ||||
| Tax and noncontrolling interests impact of above items | 0.05 | 0.05 | 0.19 | 0.14 | ||||
| Adjusted diluted earnings per share from continuing operations | $ | 0.94 | $ | 1.28 | $ | 5.18 | $ | 6.03 |
| Weighted average basic shares outstanding (in thousands) | 102,000 | 102,000 | 102,000 | 102,000 | ||||
| Weighted average dilutive shares outstanding (in thousands) | 105,000 | 105,000 | 105,000 | 105,000 | ||||
| (1) The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook. | ||||||||
| (2) The Company does not generally forecast losses from the early extinguishment of debt because the Company does not believe that it can forecast this item with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to the debt repurchased or refinanced by the Company in 2023. |
Page 21
TENET HEALTHCARE CORPORATION
Additional Supplemental Non-GAAP disclosures
Table #5 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted EBITDA
(Unaudited)
| Third Quarter 2023 | FY 2023 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (Dollars in millions) | Low | High | Low | High | ||||||||
| Net income available to Tenet Healthcare Corporation common shareholders | $ | 75 | $ | 120 | $ | 447 | $ | 582 | ||||
| Less: Net income available to noncontrolling interests | (160) | (170) | (660) | (700) | ||||||||
| Income tax expense | (65) | (75) | (315) | (335) | ||||||||
| Interest expense | (230) | (220) | (905) | (895) | ||||||||
| Loss from early extinguishment of debt(2) | — | — | (11) | (11) | ||||||||
| Other non-operating income (expense), net | (5) | — | (10) | — | ||||||||
| Net gains on sales, consolidation and deconsolidation of facilities | — | — | 13 | 13 | ||||||||
| Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1) | (30) | (20) | (125) | (75) | ||||||||
| Depreciation and amortization | (210) | (220) | (850) | (875) | ||||||||
| Adjusted EBITDA | $ | 775 | $ | 825 | $ | 3,310 | $ | 3,460 | ||||
| Income from continuing operations | $ | 75 | $ | 120 | $ | 447 | $ | 582 | ||||
| Net operating revenues | $ | 4,900 | $ | 5,100 | $ | 20,100 | $ | 20,500 | ||||
| Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues | 1.5 | % | 2.4 | % | 2.2 | % | 2.8 | % | ||||
| Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin) | 15.8 | % | 16.2 | % | 16.5 | % | 16.9 | % | ||||
| (1) The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook. | ||||||||||||
| (2) The Company does not generally forecast losses from the early extinguishment of debt because the Company does not believe that it can forecast this item with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to the debt repurchased or refinanced by the Company in 2023. |
Page 22
TENET HEALTHCARE CORPORATION
Additional Supplemental Non-GAAP disclosures
Table #6 – Reconciliations of Outlook Net Cash Provided by Operating Activities to Outlook Free Cash Flow – Continuing Operations and Outlook Adjusted Free Cash Flow – Continuing Operations
(Unaudited)
| (Dollars in millions) | FY 2023 | |||
|---|---|---|---|---|
| Low | High | |||
| Net cash provided by operating activities | $ | 1,775 | $ | 2,075 |
| Purchases of property and equipment | (675) | (725) | ||
| Free cash flow – continuing operations | $ | 1,100 | $ | 1,350 |
| Net cash provided by operating activities | $ | 1,775 | $ | 2,075 |
| Less: Payments for restructuring charges, acquisition-related costs and litigation costs and settlements(1) | (150) | (100) | ||
| Adjusted net cash provided by operating activities – continuing operations | 1,925 | 2,175 | ||
| Purchases of property and equipment | (675) | (725) | ||
| Adjusted free cash flow – continuing operations(2) | $ | 1,250 | $ | 1,450 |
| (1) The figures shown represent the Company's estimate for restructuring payments plus the actual year-to-date payments for restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast payments for acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook. | ||||
| (2) The Company’s definition of Adjusted Free Cash Flow does not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows From Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, and (ii) distributions paid to noncontrolling interests. |
Page 23